Last reviewed · How we verify
Runzaozhiyang capsule agent simulation
Runzaozhiyang capsule, marketed by Guizhou Tongjitang Pharmaceutical Co., Ltd., holds a position in the pharmaceutical market with its unique capsule agent simulation formulation. The drug's key strength lies in its protected composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Runzaozhiyang capsule agent simulation |
|---|---|
| Sponsor | Guizhou Tongjitang Pharmaceutical Co.,Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: